Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II-IIIA NSCLC patients.

We speculate that while our model shows a highly significant distinction between patients with a high or low risk of developing recurrence ( P = 0.0029, Fig. 3B ), the sensitivity and NPV of our and similar methods will not be sufficient to ethically withhold adjuvant therapy in the clinical application of a postoperative MRD‐test in stage II–III NSCLC.

also in 132,142 other papers